[1] TAKIGUCHI N,SODA H,TONOOKA T,et al. Significance of surgery for multidisciplinary treatment including neoadjuvant chemotherapy for locally advanced colorectal cancer[J]. Gan To Kagaku Ryoho,2020,47(13):2174-2176.
[2] WANG X,YU Y,MENG W,et al. Total neoadjuvant treatment (CAPOX plus radiotherapy) for patients with locally advanced rectal cancer with high risk factors: A phase 2 trial[J].Radiother Oncol,2018,129(2):300-305.
[3] 黎旭光,刘开睿,仇成江,等. 加味扶正抑瘤汤及联合吉西他滨对胰腺癌的抑制作用[J].广州中医药大学学报,2019,36(6):115-121.
[4] 中华人民共和国卫生和计划生育委员会医政医管局,中华医学会肿瘤学分会. 中国结直肠癌诊疗规范(2017年版)[J].中华外科杂志,2018,56(4):241-258.
[5] 郑筱萸. 中药新药临床研究指导原则(试行)[M]. 北京:中国医药科技出版社,2002: 41-42.
[6] 中山医科大学肿痼防治中心. 抗癌药急性及亚急性毒性反应分度标准(WHO标准)[J].癌症,1992,4(3):254.
[7] 刘秋华,林榕波. 实体瘤疗效评价标准(RECIST)指南1.1版[C].全国临床肿瘤大会暨csco学术年会,2009.
[8] 陈力. 参苓白术散合四神丸加减联合FOLFOX6化疗方案治疗脾肾阳虚型结直肠癌术后的临床研究[D]. 合肥:安徽中医药大学,2020.
[9] 乔大伟,李玉芳,张蕾,等. 128例结直肠癌肝转移患者中医证及相关因素研究[J].时珍国医国药,2020,31(1):133-136.
[10] 曲骞,杨国旺,侯炜,等. 中医辨证治疗晚期结直肠癌化疗失败患者循环肿瘤DNA状态与预后的相关性[J].中医杂志,2020,61(19):1710-1716.
[11] PETRIOLI R,FRANCINI E,CHERRI S,et al. Capecitabine plus oxaliplatin and bevacizumab,followed by maintenance treatment with capecitabine and bevacizumab for patients aged > 75 years with metastatic colorectal cancer[J].Clin Colorectal Cancer,2018,17(4):e663-e669.
[12] 周迪,朱文伟,胡明辉,等. 从自噬效应探讨“扶正祛邪法”治疗恶性肿瘤的作用及临床应用[J].辽宁中医杂志,2018,45(12):2537-2539.
[13] GALAINE J,TURCO C,VAUCHY C,et al. CD4 T cells target colorectal cancer antigens upregulated by oxaliplatin[J].Int J Cancer,2019,145(11):3112-3125.
2022, Vol. 39 
